Matching slides 303,780
Current window 205,201-205,230
Pages 10,126
Rows per page 30
Component: Titleclear collectionreset all

Component

205,201-205,230 of 303,780

filter-aware
03
The slide uses a four-column layout to summarize the market, target, product, and pipeline potential.Third Harmonic Bio | Investor Presentation Deck | 20 slides · Third Harmonic Bio
Pitch deck Investor relations 1 hit
08
The slide uses a combination of a bulleted list for qualitative benefits and a table for quantitative selectivity data.Third Harmonic Bio | Investor Presentation Deck | 20 slides · Third Harmonic Bio
Pitch deck Investor relations Beat · Product1 hit
10
The chart displays multiple dose regimens (200mg QD, 200mg BID, 500mg QD FED, 400mg BID) with error bars representing standard deviation.Third Harmonic Bio | Investor Presentation Deck | 20 slides · Third Harmonic Bio
Pitch deck Investor relations Beat · Solution1 hit
11
MAD = Multiple Ascending Dose; SAE = Serious Adverse Event; AE = Adverse Event; ANC = Absolute Neutrophil Count; PBO = Placebo.Third Harmonic Bio | Investor Presentation Deck | 20 slides · Third Harmonic Bio
Pitch deck Investor relations Beat · Solution1 hit
12
The chart tracks neutrophil levels from Day 1 to Day 70/EOS, with an 'End of treatment' marker at Day 14.Third Harmonic Bio | Investor Presentation Deck | 20 slides · Third Harmonic Bio
Pitch deck Investor relations Beat · Solution1 hit
13
Includes a disclaimer about the reliability of cross-study comparisons.Third Harmonic Bio | Investor Presentation Deck | 20 slides · Third Harmonic Bio
Pitch deck Investor relations Beat · Solution1 hit
14
Includes two line charts with error bars representing mean +/- SD. LLOQ marked on the absolute chart.Third Harmonic Bio | Investor Presentation Deck | 20 slides · Third Harmonic Bio
Pitch deck Investor relations Beat · Solution1 hit
15
The schematic illustrates a dose-escalation study with three cohorts of 10 patients each, followed by a 4-week follow-up period.Third Harmonic Bio | Investor Presentation Deck | 20 slides · Third Harmonic Bio
Pitch deck Investor relations 1 hit
16
Data presented as Mean ± SD. Logarithmic scale on Y-axis.Third Harmonic Bio | Investor Presentation Deck | 20 slides · Third Harmonic Bio
Pitch deck Investor relations 1 hit
18
The slide outlines a randomized, placebo-controlled trial structure with specific weeks and days for allergen challenges and measurements.Third Harmonic Bio | Investor Presentation Deck | 20 slides · Third Harmonic Bio
Pitch deck Investor relations 1 hit
20
Third Harmonic Bio | Investor Presentation Deck | 20 slidesThird Harmonic Bio | Investor Presentation Deck | 20 slides · Third Harmonic Bio
Pitch deck Investor relations 1 hit
02
Tonix Pharmaceuticals | Investor Presentation Deck | 29 slidesTonix Pharmaceuticals | Investor Presentation Deck | 29 slides · Tonix Pharmaceuticals
Conference presentation Investor relations 1 hit
03
Tonix Pharmaceuticals | Investor Presentation Deck | 29 slidesTonix Pharmaceuticals | Investor Presentation Deck | 29 slides · Tonix Pharmaceuticals
Conference presentation Investor relations Beat · ProblemLoop · Golden Circle1 hit
04
Tonix Pharmaceuticals | Investor Presentation Deck | 29 slidesTonix Pharmaceuticals | Investor Presentation Deck | 29 slides · Tonix Pharmaceuticals
Conference presentation Investor relations Beat · ProblemLoop · Golden Circle1 hit
05
The slide provides a comprehensive overview of clinical and preclinical programs with detailed footnotes explaining specific drug statuses and licensing agreements.Tonix Pharmaceuticals | Investor Presentation Deck | 29 slides · Tonix Pharmaceuticals
Conference presentation Investor relations Beat · ProblemLoop · Golden Circle1 hit
06
Tonix Pharmaceuticals | Investor Presentation Deck | 29 slidesTonix Pharmaceuticals | Investor Presentation Deck | 29 slides · Tonix Pharmaceuticals
Conference presentation Investor relations Loop · Golden Circle1 hit
07
The slide uses a split-layout: left side describes the drug product, right side lists clinical trial status for Fibromyalgia, Long COVID, and PTSD.Tonix Pharmaceuticals | Investor Presentation Deck | 29 slides · Tonix Pharmaceuticals
Conference presentation Investor relations Beat · SolutionLoop · Golden Circle1 hit
08
Includes clinical trial status (RELIEF, RALLY, RESILIENT) and market demographics.Tonix Pharmaceuticals | Investor Presentation Deck | 29 slides · Tonix Pharmaceuticals
Conference presentation Investor relations Beat · SolutionLoop · Golden Circle1 hit
09
Clinical trial design slide for Tonix Pharmaceuticals.Tonix Pharmaceuticals | Investor Presentation Deck | 29 slides · Tonix Pharmaceuticals
Conference presentation Investor relations Beat · SolutionLoop · Golden Circle1 hit
10
Slide 10 of a corporate presentation deck.Tonix Pharmaceuticals | Investor Presentation Deck | 29 slides · Tonix Pharmaceuticals
Conference presentation Investor relations Beat · SolutionLoop · Golden Circle1 hit
11
The slide outlines a clinical trial protocol for TNX-102 SL in Long COVID patients.Tonix Pharmaceuticals | Investor Presentation Deck | 29 slides · Tonix Pharmaceuticals
Conference presentation Investor relations Beat · SolutionLoop · Golden Circle1 hit
12
Includes disclaimer about non-approval and patent status.Tonix Pharmaceuticals | Investor Presentation Deck | 29 slides · Tonix Pharmaceuticals
Conference presentation Investor relations Beat · SolutionLoop · Golden Circle1 hit
13
Slide 13 of a Tonix Pharmaceuticals presentation.Tonix Pharmaceuticals | Investor Presentation Deck | 29 slides · Tonix Pharmaceuticals
Conference presentation Investor relations Beat · SolutionLoop · Golden Circle1 hit
14
Includes clinical trial status and mechanism of action highlights.Tonix Pharmaceuticals | Investor Presentation Deck | 29 slides · Tonix Pharmaceuticals
Conference presentation Investor relations Beat · SolutionLoop · Golden Circle1 hit
15
Slide provides a high-level summary of a pharmaceutical asset's profile and development roadmap.Tonix Pharmaceuticals | Investor Presentation Deck | 29 slides · Tonix Pharmaceuticals
Conference presentation Investor relations Beat · SolutionLoop · Golden Circle1 hit
16
Tonix Pharmaceuticals | Investor Presentation Deck | 29 slidesTonix Pharmaceuticals | Investor Presentation Deck | 29 slides · Tonix Pharmaceuticals
Conference presentation Investor relations Beat · Market SizeLoop · Golden Circle1 hit
17
The slide uses a two-column layout to contrast the disease profile with the development program status.Tonix Pharmaceuticals | Investor Presentation Deck | 29 slides · Tonix Pharmaceuticals
Conference presentation Investor relations Beat · Market SizeLoop · Golden Circle1 hit
18
Tonix Pharmaceuticals | Investor Presentation Deck | 29 slidesTonix Pharmaceuticals | Investor Presentation Deck | 29 slides · Tonix Pharmaceuticals
Conference presentation Investor relations Beat · Market SizeLoop · Golden Circle1 hit
20
The slide outlines a drug development asset in the immunology portfolio.Tonix Pharmaceuticals | Investor Presentation Deck | 29 slides · Tonix Pharmaceuticals
Conference presentation Investor relations Loop · Golden Circle1 hit
21
Tonix Pharmaceuticals | Investor Presentation Deck | 29 slidesTonix Pharmaceuticals | Investor Presentation Deck | 29 slides · Tonix Pharmaceuticals
Conference presentation Investor relations Loop · Golden Circle1 hit